Lyell Immunopharma Announces Participation in Upcoming Investor Conferences
Lyell Immunopharma (Nasdaq: LYEL), a clinical-stage company focused on developing next-generation CAR T-cell therapies for cancer patients, has announced its participation in two upcoming investor conferences. The company's senior management team will present at:
- The H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25th at 2:30 pm Eastern Time
- The TD Cowen's 45th Annual Health Care Conference on March 3rd at 11:50 am Eastern Time
Interested parties can access live webcasts of the presentations through the Investors section of Lyell's website (www.lyell.com). Replay options will be available on the company's website following the live presentations.
Lyell Immunopharma (Nasdaq: LYEL), un'azienda in fase clinica focalizzata sullo sviluppo di terapie avanzate con cellule CAR T per pazienti oncologici, ha annunciato la sua partecipazione a due prossimi convegni per investitori. Il team di gestione senior dell'azienda presenterà:
- La 3ª Conferenza Virtuale Annuale sulla Terapia Cellulare H.C. Wainwright il 25 febbraio alle 14:30 ora orientale
- La 45ª Conferenza Annuale sulla Salute di TD Cowen il 3 marzo alle 11:50 ora orientale
Le parti interessate possono accedere alle dirette web delle presentazioni attraverso la sezione Investitori del sito web di Lyell (www.lyell.com). Opzioni di replay saranno disponibili sul sito dell'azienda dopo le presentazioni dal vivo.
Lyell Immunopharma (Nasdaq: LYEL), una empresa en etapa clínica centrada en desarrollar terapias de células CAR T de nueva generación para pacientes con cáncer, ha anunciado su participación en dos próximas conferencias para inversores. El equipo de alta dirección de la empresa presentará en:
- La 3ª Conferencia Virtual Anual de Terapia Celular H.C. Wainwright el 25 de febrero a las 2:30 p.m. hora del Este
- La 45ª Conferencia Anual de Salud de TD Cowen el 3 de marzo a las 11:50 a.m. hora del Este
Las partes interesadas pueden acceder a las transmisiones en vivo de las presentaciones a través de la sección de Inversores del sitio web de Lyell (www.lyell.com). Las opciones de repetición estarán disponibles en el sitio web de la empresa después de las presentaciones en vivo.
Lyell Immunopharma (Nasdaq: LYEL)는 암 환자를 위한 차세대 CAR T 세포 치료제를 개발하는 임상 단계 회사로, 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 회사의 고위 경영진 팀은 다음과 같은 발표를 할 것입니다:
- H.C. Wainwright 제3회 연례 세포 치료 가상 회의가 2월 25일 동부 시간으로 오후 2시 30분에 개최됩니다.
- TD Cowen의 제45회 연례 건강 관리 회의가 3월 3일 동부 시간으로 오전 11시 50분에 개최됩니다.
관심 있는 분들은 Lyell 웹사이트의 투자자 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다 (www.lyell.com). 생중계 발표 후에는 회사 웹사이트에서 재생 옵션을 이용할 수 있습니다.
Lyell Immunopharma (Nasdaq: LYEL), une entreprise en phase clinique spécialisée dans le développement de thérapies par cellules CAR T de nouvelle génération pour les patients atteints de cancer, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'équipe de direction senior de l'entreprise présentera lors des événements suivants :
- La 3ème Conférence Virtuelle Annuelle sur la Thérapie Cellulaire H.C. Wainwright le 25 février à 14h30 heure de l'Est
- La 45ème Conférence Annuelle sur la Santé de TD Cowen le 3 mars à 11h50 heure de l'Est
Les parties intéressées peuvent accéder aux webdiffusions en direct des présentations via la section Investisseurs du site web de Lyell (www.lyell.com). Des options de rediffusion seront disponibles sur le site de l'entreprise après les présentations en direct.
Lyell Immunopharma (Nasdaq: LYEL), ein Unternehmen in der klinischen Phase, das sich auf die Entwicklung von CAR-T-Zelltherapien der nächsten Generation für Krebspatienten konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben. Das Senior Management-Team des Unternehmens wird bei folgenden Veranstaltungen präsentieren:
- Der 3. Virtuelle Zelltherapiekonferenz von H.C. Wainwright am 25. Februar um 14:30 Uhr Eastern Time
- Der 45. Jährliche Gesundheitskonferenz von TD Cowen am 3. März um 11:50 Uhr Eastern Time
Interessierte Parteien können die Live-Übertragungen der Präsentationen über den Investorenbereich der Website von Lyell (www.lyell.com) abrufen. Wiederholungsoptionen werden nach den Live-Präsentationen auf der Website des Unternehmens verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced today that members of its senior management team will present and participate the following upcoming investor conferences:
- H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on February 25th at 2:30 pm Eastern Time
- TD Cowen's 45th Annual Health Care Conference on March 3rd at 11:50 am Eastern Time
A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website.
About Lyell
Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. Lyell is based in South San Francisco, California with facilities in West Hills, California and Seattle and Bothell, Washington. To learn more, please visit www.lyell.com.
Contact:
Ellen Rose
Senior Vice President, Communications and Investor Relations
erose@lyell.com
FAQ
When is Lyell Immunopharma (LYEL) presenting at the H.C. Wainwright Cell Therapy Conference?
What time is LYEL's presentation at the TD Cowen Healthcare Conference?
How can investors access Lyell Immunopharma's (LYEL) upcoming conference presentations?
What type of therapies is Lyell Immunopharma (LYEL) developing?
